SLC5A2 and chronic kidney disease: This practice likely stems from the diminished efficacy of SGLT2 inhibitors in promoting glucosuria and natriuresis as kidney function declines [8, 9], coupled with undetermined safety profiles among patients with advanced CKD or ESKD who were historically excluded from pivotal clinical trials.